Management of Serotonin Syndrome (Serotonin Toxicity)

Pathophysiology

• Increase serotonin synthesis (L-tryptophan)
• Increase serotonin release (amphetamines, MDMA, cocaine)
• Inhibit serotonin reuptake (SSRIs, SNRIs, TCAs, meperidine, tramadol, dextromethorphan)
• Inhibit serotonin metabolism (MAOIs, linezolid)
• Act as direct 5-HT receptor agonists (triptans, buspirone, LSD)
• Impair serotonin clearance (lithium)

• Rosen's Emergency Medicine, p. 2925; Washington Manual, p. 1072

Clinical Features: The Classic Triad

• Clonus (inducible, spontaneous, or ocular) - especially prominent in the ankles/lower extremities - is the hallmark
• "Lead-pipe" rigidity of all four limbs is NOT serotonin syndrome (suggests NMS instead)
• Hyperthermia is a late, ominous sign - its absence does not rule out the syndrome
• Onset is rapid: typically within hours of exposure (same day)
• Tintinalli's Emergency Medicine, p. 1244; Washington Manual, p. 1072

Diagnosis: Hunter Criteria

1. Spontaneous clonus
2. Inducible clonus + agitation or diaphoresis
3. Ocular clonus + agitation or diaphoresis
4. Tremor + hyperreflexia
5. Hypertonia + temperature >38°C + ocular or inducible clonus

• Rosen's Emergency Medicine (Hunter Criteria), p. 2925

Differential Diagnosis

• Tintinalli's Emergency Medicine, p. 1244-1245; Washington Manual, p. 1072

Management: Step-by-Step

Step 1 - Discontinue All Serotonergic Agents (Immediate)

Step 2 - Supportive Care by Severity

Mild Serotonin Syndrome

• Discontinue offending agent(s)
• Observation and monitoring
• Low-dose benzodiazepines (e.g., diazepam 5-10 mg IV) for agitation and muscle rigidity

Moderate Serotonin Syndrome

• IV fluid resuscitation
• Benzodiazepines liberally - large doses may be required (diazepam 10-20 mg IV, titrated in 10 mg aliquots)
• Goal: patient resting comfortably with normal neuromuscular tone and improving vital signs
• Cyproheptadine (see below) may have a role here

Severe Serotonin Syndrome

• Endotracheal intubation + mechanical ventilation (~25% of patients)
• Deep sedation with benzodiazepines or other sedative-hypnotics
• Nondepolarizing neuromuscular blockade (e.g., rocuronium for RSI) if hyperthermia is refractory to sedation
  • If additional paralysis needed: vecuronium 10 mg IV single dose
  • Do NOT use succinylcholine (depolarizing agent) - risk of hyperkalemia from rhabdomyolysis
• ICU admission
• Rosen's Emergency Medicine, p. 2925; Tintinalli's, p. 1247; Washington Manual, p. 1072

Step 3 - Temperature Management

• Antipyretic medications (NSAIDs, acetaminophen) are NOT effective - they target central prostaglandin pathways and have no role
• Aggressive cooling is mandatory for any degree of hyperthermia:
  • First choice: evaporative cooling (spray patient with tepid water + fan)
  • Alternative: immersion in ice water bath
• Aggressive benzodiazepine sedation (and paralysis if needed) directly reduces heat generation
• Washington Manual, p. 1072-1073; Roberts & Hedges' Clinical Procedures in Emergency Medicine

Step 4 - Specific Antidotal Therapy

Cyproheptadine (5-HT2A antagonist)

• An antihistamine with serotonin antagonist and anticholinergic properties
• Used off-label - only available in oral form
• Indication: Moderate cases, or severe/refractory cases when diagnosis is confident
• Dosing: Initial dose 12 mg PO, then 2 mg every 2 hours until clinical improvement (Tintinalli's); some sources recommend 12 mg as a single dose for severe cases (Rosen's)
• Caution: Do NOT give if anticholinergic toxicity remains on the differential - cyproheptadine will worsen it
• Limitations: No RCT evidence; a 2025 systematic review (PMID: 39791184) examined its efficacy in deliberate self-poisoning and found limited high-quality evidence

Chlorpromazine

• 5-HT2A receptor antagonist available in parenteral form
• Some reports of successful treatment
• Disadvantages: Can cause hypotension; blocks dopamine receptors (may promote rigidity, lower seizure threshold, worsen NMS if diagnosis is uncertain)
• Dopamine agonists (bromocriptine) have NO role in serotonin syndrome - Tintinalli's, p. 1247
• Dantrolene - sometimes used but clinical benefit is unproven; NOT the same as its role in malignant hyperthermia - Katzung's, p. 451

Step 5 - Monitoring and Investigations

• Rhabdomyolysis - from sustained muscle rigidity
• Metabolic acidosis - from hyperthermia and muscle activity
• Acute kidney injury - secondary to rhabdomyolysis
• Disseminated intravascular coagulation (DIC) - rare, extreme hyperthermia

Disposition

• Most patients show dramatic improvement within 24 hours of stopping the offending agent(s)
• Exception: fluoxetine and its active metabolite have very long half-lives - symptoms may persist longer
• After recovery: avoid all serotonergic drugs in the future

Key Points Summary

1. Discontinue all serotonergic agents - the most important step
2. Benzodiazepines are the cornerstone of pharmacological management - use liberally
3. Hyperthermia = medical emergency - cooling is aggressive and antipyretics are useless
4. Intubation + paralysis with nondepolarizing agents for severe/refractory cases
5. Cyproheptadine is an adjunct for moderate cases only (oral, no RCT evidence)
6. Dantrolene does NOT work (unlike malignant hyperthermia)
7. Do not confuse with NMS - management differs fundamentally

Recent evidence note: A 2026 systematic review (PMID: 42463509) analyzing precipitants and clinical features of serotonin syndrome from published case reports was released in July 2026 - this may update the epidemiological picture. A 2025 systematic review on cyproheptadine (PMID: 39791184) found insufficient RCT-level evidence to fully define its role; its use remains empirical.